Cancer BiologybioRxivPreprint
Integrated ex vivo screening and transcriptomic profiling to prioritize drug combinations for rare cancers
Ritu C. Shah, Alex T. Larsson, Belinda B. Garana…·Sara J.C. Gosline
The paper develops EXACT, a framework combining ex vivo drug screening with transcriptomic analysis to identify effective drug combinations for rare cancers, finding a MEK and HDAC inhibitor combination shows enhanced activity.
DOI 10.64898/2026.07.28.741264